February 29, 2012 — Vessix Vascular Inc. announced initial patient treatments in the international multi-center Reduce-HTN renal denervation clinical study for uncontrolled hypertension.

February 29, 2012 — Lantheus Medical Imaging Inc. announced a strategic distribution arrangement for its Definity cardiac ultrasound contrast agent in the People’s Republic of China, including Hong Kong S.A.R. and Macau S.A.R.

February 28, 2012 — Janssen Research and Development LLC announced that the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug application (sNDA) filed Dec. 29, 2011 for Xarelto (rivaroxaban).


Based on what readers clicked on throughout 2011 on DIcardiology.com, following is a list of the top 25 most popular stories.

 

February 28, 2012 — AccessClosure Inc. announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the MynxGrip Vascular Closure Device (VCD). Built on the Mynx platform, the MynxGrip VCD offers an active, extravascular and patient-friendly vascular closure solution.

February 28, 2012 — nContact Inc. announced a new preclinical study examining a unique minimally invasive percutaneous approach to accessing the heart that may enable electrophysiologists (EPs) to perform epicardial ablation for ventricular tachycardia (VT). The study was published in the February 2012 issue of The Journal of Innovations in Cardiac Rhythm Management.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now